Loading…
EYPT
EyePoint, Inc.
NASDAQ· Healthcare· Biotechnology
$4.48-3.24%
Key metrics
- Market cap
- $375.61M
- P/E
- —
- Forward P/E
- —
- P/B
- 11.3x
- Dividend yield
- —
- EPS
- -$3.64
- ROE
- -148.70%
- Profit margin
- 0.00%
- Revenue growth
- +161.70%
- Beta
- 1.74
- 52-week high
- $19.11
- 52-week low
- $3.95
History
How the company evolved, year by year. Revenue and debt come from the annual statements; dividends from the payments themselves, which reach further back.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
About the company
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.
- 214
- Watertown, United States
Company description provided by Yahoo Finance.